Evaluating the administration costs of biologic drugs: development of a cost algorithm

Ebenezer K. Tetteh, Stephen Morris

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)

Abstract

Biologic drugs, as with all other medical technologies, are subject to a number of regulatory, marketing, reimbursement (financing) and other demand-restricting hurdles applied by healthcare payers. One example is the routine use of cost-effectiveness analyses or health technology assessments to determine which medical technologies offer value-for-money. The manner in which these assessments are conducted suggests that, holding all else equal, the economic value of biologic drugs may be determined by how much is spent on administering these drugs or trade-offs between drug acquisition and administration costs. Yet, on the supply-side, it seems very little attention is given to how manufacturing and formulation choices affect healthcare delivery costs. This paper evaluates variations in the administration costs of biologic drugs, taking care to ensure consistent inclusion of all relevant cost resources. From this, it develops a regression-based algorithm with which manufacturers could possibly predict, during process development, how their manufacturing and formulation choices may impact on the healthcare delivery costs of their products.

Original languageEnglish
JournalJournal of Internet Services and Applications
Volume4
Issue number1
DOIs
Publication statusPublished - 2014
Externally publishedYes

Keywords

  • Administration costs
  • Biologics
  • Economic evaluation
  • Formulation
  • Manufacturing

Fingerprint

Dive into the research topics of 'Evaluating the administration costs of biologic drugs: development of a cost algorithm'. Together they form a unique fingerprint.

Cite this